 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. National Institutes of Health
Chronic Hepatitis C: Current Disease ManagementImmunostaining
September 20, 1998 Immunostaining using polyclonal or monoclonal antibodies to detect HCV antigens in the liver has been reported to be useful. However, these tests are not commercially available, and even in the hands of research investigators, immunostaining detects HCV antigens in liver tissue in only 60 to 70 percent of patients with chronic hepatitis C -- largely in those with high levels of HCV in serum. This test also requires special handling of liver tissue and thus is not appropriate for routine clinical use.
This article was provided by U.S. National Institutes of Health. |
E-Mail
Printable Single-Page
Glossary
Share
